A Phase 3 interventional study of Apremilast and Etanercept in Psoriasis and Psoriatic Arthritis, sponsored by Amgen. Completed at 82 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-15.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing apremilast in Arthritis, Psoriatic — 3 open to participants now, 3 under way, 1 of them phase 3. apremilast · Arthritis, Psoriatic.
Among the 17 studies testing apremilast in Arthritis, Psoriatic, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 8 in phase 3, and was the 6th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →3 of the 17 studies testing apremilast in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
Tanta University · Sites in Egypt
Ages 18–70
Amgen
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 219 across the 17 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 7 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
21 studies in Arthritis, Psoriatic by Amgen: 1 open now, 1 under way, none of them phase 3. Of 20 finished, 13 (65%) have results posted.
Among the 21 studies in Arthritis, Psoriatic by Amgen, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2012, is one of 9 in phase 3, and was the 8th registered.
Amgen’s Arthritis, Psoriatic studies by the year they started, since 2000.
2 of the studies testing apremilast in Arthritis, Psoriatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07398651Tanta UniversityApremilast and Adalimumab in Psoriatic Arthritis Patients | 2026-12-30 |
| NCT07908641AmgenComparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release Formulation | 2027-01-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing apremilast in Arthritis, Psoriatic, from their registry updates:
Among Amgen’s 21 in Arthritis, Psoriatic:
This tab as a report to print or save as PDF → With an account.
This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis.
This is a phase 3b, multicenter, randomized, placebo-controlled, double-blind, double-dummy, study of the efficacy and safety of apremilast, etanercept, and placebo, in adults with moderate to severe plaque psoriasis.
250 participants will be randomized 1:1:1 to the three treatment groups. All subjects will receive both tablets and injections through Week 16.
The study will consist of four phases:
During the double-blind, placebo-controlled phase, subjects will receive treatment with one of the following:
All subjects will be asked to participate in a 4-week Post-treatment Observational Follow-up Phase either upon completion of the study or upon discontinuation of investigational product for those subjects who terminate the study early.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
This study's enrollment of 250 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Browse Arthritis, Psoriatic studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Apremilast 30 mg tablets orally twice a day (BID) plus once weekly (QW) evaluator/subject-blinded subcutaneous (SC) saline (placebo) injections
Drug: Apremilast · Drug: Placebo injection
Etanercept 50 mg evaluator/subject-blinded SC QW injections plus placebo tablets orally BID
Drug: Etanercept · Drug: Placebo tablet
Identically matching placebo tablets and evaluator/subject-blinded SC injections
Drug: Placebo tablet · Drug: Placebo injection
Apremilast 30 mg tablet orally BID
Also known as: CC-10004, Otezla
Etanercept 50 mg evaluator/subject-blinded SC QW injection
Also known as: Enbrel
Placebo tablets BID
Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at Week 16 From Baseline
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.
Time frame: Baseline to Week 16
Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI) for the Comparison Between Etanercept 50mg SC QW and Placebo at Week 16
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.
Time frame: Baseline and Week 16
Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16
The sPGA is an assessment by the Investigator of the overall disease severity at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. When making the assessment of overall severity, the Investigator should factor in areas that have already been cleared (ie, have scores of 0) and not just evaluate remaining lesions for severity, ie, the severity of each sign is averaged across all areas of involvement, including cleared lesions. In the event of different severities across disease signs, the sign that is the predominant feature of the disease should be used to help determine the sPGA score.
Time frame: Baseline and Week 16
Percent Change From Baseline in the Affected Body Surface Area (BSA) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16
BSA is a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. BSA percent change from baseline was determined at each visit of the study, and is calculated as 100\*(post-baseline BSA - baseline BSA) / baseline BSA.
Time frame: Baseline to Week 16
Percentage of Participants Who Achieved a 50% Improvement (Response) in the Psoriasis Area Severity Index (PASI-50) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16
PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.
Time frame: Baseline to Week 16
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score In Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16
DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.
Time frame: Baseline to Week 16
Change From Baseline in the Mental Component Summary (MCS) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16
The SF-36 is a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Scores from the 8 scales were transformed to the norm-based scores using weights from U.S. general population to have a mean of 50 and variance = 10, with higher scores indicating better health. From these 8 scale, two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS), both having the same mean of 50 and variance = 10 as noted for the individual scales for the U.S. general population, and with higher scores indicating better health. For MCS, change from baseline was calculated, where change = visit value - baseline value.
Time frame: Baseline to Week 16
Percentage of Participants Who Achieved a Lattice System Physician's Global Assessment (LS-PGA) Score of Clear (0) or Almost Clear at Week 16 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16
The Lattice System Physician's Global Assessment is a global assessment performed by the investigator of psoriasis severity. Integrating ranges of BSA involvement with assessments of overall plaque severity (using a 4 point scale from none to marked for the signs of plaque elevation, erythema and scale), the LS-PGA produces an overall assessment of psoriasis severity on an 8-point scale, ranging from clear to very severe. To determine the final score, the lattice portion is governed by the BSA and among the plaque qualities, weights plaque elevation as most important, erythema next, and scale least.
Time frame: Baseline to Week 16
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Phase
A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug for participants who discontinued early. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, clinically significant adverse change in frequency or intensity of a preexisting condition) should be considered an AE. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above.
Time frame: Week 0 to Week 16; mean duration of exposure was 14.90 weeks for placebo group, 15.13 weeks for apremilast group and 15.87 weeks for Etanercept group
Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Apremilast-exposure Period
A TEAE in the apremilast-exposure phase is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes listed above.
Time frame: From the first dose of apremilast (either Week 0 for participants originally randomized to apremilast or Week 16 for those originally randomized to placebo or etanercept who were switched to apremilast at week 16) until 28 days after last apremilast dose
Psoriasis Flare/Rebound
Psoriasis flare is an AE and represents an atypical or unusual worsening of disease during treatment. It is defined as a sudden intensification of psoriasis requiring medical intervention or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is an AE and is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. This exacerbation is characterized by a PASI ≥125% of baseline or a new generalized pustular, erythrodermic, or more inflammatory psoriasis after stopping therapy.
Time frame: Week 0 to Week 16; Placebo controlled phase
Psoriasis Flare/Rebound
Psoriasis flare is an AE and represents an atypical or unusual worsening of disease during treatment. It is defined as a sudden intensification of psoriasis requiring medical intervention or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is an AE and is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. This exacerbation is characterized by a PASI ≥125% of baseline or a new generalized pustular, erythrodermic, or more inflammatory psoriasis after stopping therapy. PASI ≥125% of baseline score at any visit after the last dose date for those who discontinued within the phase.
Time frame: From the first dose of apremilast (either Week 0 or Week 16 for participants originally randomized to placebo or etanercept who were switched at Week 16) until 28 days after the last dose of apremilast.
The study was conducted at 65 study centers in 11 countries.
| Milestone | Placebo | Apremilast Plus Placebo Injection | Etanercept Plus Placebo Tablet | Placebo/Apremilast | Apremilast/Apremilast | Etanercept/Apremilast |
|---|---|---|---|---|---|---|
| Started | 84 | 83 | 83 | 0 | 0 | 0 |
| Safety population | 84 | 83 | 83 | 0 | 0 | 0 |
| Completed | 75 | 77 | 81 | 0 | 0 | 0 |
| Not completed | 9 | 6 | 2 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 4 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 2 | 1 | 1 | 0 | 0 | 0 |
| Milestone | Placebo | Apremilast Plus Placebo Injection | Etanercept Plus Placebo Tablet | Placebo/Apremilast | Apremilast/Apremilast | Etanercept/Apremilast |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 73 | 74 | 80 |
| Safety population | 0 | 0 | 0 | 73 | 74 | 79 |
| Completed | 0 | 0 | 0 | 47 | 41 | 50 |
| Not completed | 0 | 0 | 0 | 26 | 33 | 30 |
| Withdrew: Adverse event | 0 | 0 | 0 | 3 | 4 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 9 | 10 | 8 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 8 | 5 | 11 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 6 | 13 | 6 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 1 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.
| Percentage of participants | Placebo | Apremilast Plus Placebo Injection |
|---|---|---|
| Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at Week 16 From Baseline | 11.9 | 39.8 |
PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.
| percentage of participants | Placebo | Etanercept 50mg Plus Placebo Tablet |
|---|---|---|
| Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI) for the Comparison Between Etanercept 50mg SC QW and Placebo at Week 16 | 11.9 | 48.2 |
The sPGA is an assessment by the Investigator of the overall disease severity at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. When making the assessment of overall severity, the Investigator should factor in areas that have already been cleared (ie, have scores of 0) and not just evaluate remaining lesions for severity, ie, the severity of each sign is averaged across all areas of involvement, including cleared lesions. In the event of different severities across disease signs, the sign that is the predominant feature of the disease should be used to help determine the sPGA score.
| percentage of participants | Placebo | Apremilast Plus Placebo Injection | Etanercept Plus Placebo Tablet |
|---|---|---|---|
| Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16 | 3.6 | 21.7 | 28.9 |
BSA is a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area. BSA percent change from baseline was determined at each visit of the study, and is calculated as 100\*(post-baseline BSA - baseline BSA) / baseline BSA.
| percent change | Placebo | Apremilast Plus Placebo Injection | Etanercept Plus Placebo Tablets |
|---|---|---|---|
| Percent Change From Baseline in the Affected Body Surface Area (BSA) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16 | -16.3 (-23.71 to -8.81) | -47.7 (-55.20 to -40.12) | -56.1 (-63.63 to -48.59) |
PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.
| percentage of participants | Placebo | Apremilast Plus Placebo Injection | Etanercept Plus Placebo Tablet |
|---|---|---|---|
| Percentage of Participants Who Achieved a 50% Improvement (Response) in the Psoriasis Area Severity Index (PASI-50) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16 | 33.3 | 62.7 | 83.1 |
DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.
| units on a scale | Placebo | Apremilast 30mg Plus Placebo Injection | Etanercept 50mg Plus Placebo Tablet |
|---|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score In Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16 | -3.9 (-5.34 to -2.42) | -8.4 (-9.84 to -6.88) | -7.8 (-9.28 to -6.34) |
The SF-36 is a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Scores from the 8 scales were transformed to the norm-based scores using weights from U.S. general population to have a mean of 50 and variance = 10, with higher scores indicating better health. From these 8 scale, two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS), both having the same mean of 50 and variance = 10 as noted for the individual scales for the U.S. general population, and with higher scores indicating better health. For MCS, change from baseline was calculated, where change = visit value - baseline value.
| units on a scale | Placebo | Apremilast Plus Placebo Injection | Etanercept Plus Placebo Tablets |
|---|---|---|---|
| Change From Baseline in the Mental Component Summary (MCS) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16 | 2.6 (0.72 to 4.43) | 3.5 (1.62 to 5.38) | 4.8 (2.92 to 6.67) |
The Lattice System Physician's Global Assessment is a global assessment performed by the investigator of psoriasis severity. Integrating ranges of BSA involvement with assessments of overall plaque severity (using a 4 point scale from none to marked for the signs of plaque elevation, erythema and scale), the LS-PGA produces an overall assessment of psoriasis severity on an 8-point scale, ranging from clear to very severe. To determine the final score, the lattice portion is governed by the BSA and among the plaque qualities, weights plaque elevation as most important, erythema next, and scale least.
| percentage of participants | Placebo | Apremilast Plus Placebo Injection | Etanercept Plus Placebo Tablets |
|---|---|---|---|
| Percentage of Participants Who Achieved a Lattice System Physician's Global Assessment (LS-PGA) Score of Clear (0) or Almost Clear at Week 16 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16 | 6.0 | 24.1 | 22.9 |
A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug for participants who discontinued early. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, clinically significant adverse change in frequency or intensity of a preexisting condition) should be considered an AE. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above.
| participants | Placebo | Apremilast Plus Placebo Injection | Etanercept Plus Placebo Tablets |
|---|---|---|---|
| Any TEAE | 45 | 59 | 44 |
| Any Drug-related TEAE | 17 | 27 | 21 |
| Any Severe TEAE | 2 | 3 | 3 |
| Any Serious TEAE | 0 | 3 | 2 |
| Any Serious Drug-related TEAE | 0 | 2 | 1 |
| Any TEAE Leading to Drug Interruption | 1 | 9 | 3 |
| Any TEAE Leading to Drug Withdrawal | 2 | 3 | 2 |
| Any TEAE Leading to Death | 0 | 0 | 0 |
A TEAE in the apremilast-exposure phase is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes listed above.
| participants | Placebo/Apremilast | Apremilast/Apremilast | Etanercept/Apremilast |
|---|---|---|---|
| Any TEAE | 45 | 71 | 54 |
| Any Drug-related TEAE | 23 | 36 | 15 |
| Any Severe TEAE | 4 | 7 | 7 |
| Any Serious TEAE | 5 | 6 | 4 |
| Any Serious Drug-related TEAE | 2 | 2 | 1 |
| Any TEAE Leading to Drug Interruption | 8 | 13 | 7 |
| Any TEAE Leading to Drug Withdrawal | 3 | 7 | 2 |
| Any TEAE Leading to Death | 0 | 0 | 0 |
Psoriasis flare is an AE and represents an atypical or unusual worsening of disease during treatment. It is defined as a sudden intensification of psoriasis requiring medical intervention or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is an AE and is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. This exacerbation is characterized by a PASI ≥125% of baseline or a new generalized pustular, erythrodermic, or more inflammatory psoriasis after stopping therapy.
| participants | Placebo | Apremilast Plus Placebo Injection | Etanercept Plus Placebo Tablets |
|---|---|---|---|
| Any psoriasis flare captured as a TEAE | 3 | 1 | 0 |
| Any psoriasis rebound captured as a TEAE | 0 | 0 | 0 |
| Those with PASI ≥125% baseline score and D/C APR | 1 | 0 | 0 |
Psoriasis flare is an AE and represents an atypical or unusual worsening of disease during treatment. It is defined as a sudden intensification of psoriasis requiring medical intervention or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is an AE and is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. This exacerbation is characterized by a PASI ≥125% of baseline or a new generalized pustular, erythrodermic, or more inflammatory psoriasis after stopping therapy. PASI ≥125% of baseline score at any visit after the last dose date for those who discontinued within the phase.
| participants | Placebo/Apremilast | Apremilast/Apremilast | Etanercept/Apremilast |
|---|---|---|---|
| Any psoriasis flare captured as a TEAE | 1 | 4 | 0 |
| Any psoriasis rebound captured as a TEAE | 1 | 2 | 7 |
| Those with PASI ≥125% baseline score and D/C APR | 0 | 0 | 1 |
Collected over Adverse events are reported for the 16-week placebo-controlled period and up to week 104 during the apremilast exposure period for all participants who were randomized or switched to apremilast at any time during the course of the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Week 0-16) | — | 0/84 (0%) | 25/84 (29.8%) |
| Apremilast Plus Placebo Injection (Week 0-16) | — | 3/83 (3.6%) | 41/83 (49.4%) |
| Etanercept Plus Placebo Tablets (Week 0-16) | — | 2/83 (2.4%) | 27/83 (32.5%) |
| Placebo/APR 30mg (Apremilast Exposure Phase) Weeks 16-104 | — | 5/73 (6.8%) | 30/73 (41.1%) |
| APR/APR 30 mg (Apremilast Exposure Phase) Weeks 0-104 | — | 6/83 (7.2%) | 52/83 (62.7%) |
| Etanercept/APR 30mg (Apremilast Exposure Phase) Weeks 16-104 | — | 4/79 (5.1%) | 32/79 (40.5%) |
| Event | Placebo (Week 0-16) | Apremilast Plus Placebo Injection (Week 0-16) | Etanercept Plus Placebo Tablets (Week 0-16) | Placebo/APR 30mg (Apremilast Exposure Phase) Weeks 16-104 | APR/APR 30 mg (Apremilast Exposure Phase) Weeks 0-104 | Etanercept/APR 30mg (Apremilast Exposure Phase) Weeks 16-104 |
|---|---|---|---|---|---|---|
| Non-cardiac chest painGeneral disorders | 0/84 | 0/83 | 0/83 | 1/73 | 0/83 | 0/79 |
| CholelithiasisHepatobiliary disorders | 0/84 | 0/83 | 0/83 | 1/73 | 0/83 | 0/79 |
| Anogenital wartsInfections and infestations | 0/84 | 0/83 | 0/83 | 1/73 | 0/83 | 0/79 |
| Traumatic intracranial haemorrhageInjury, poisoning and procedural complications | 0/84 | 0/83 | 0/83 | 1/73 | 0/83 | 0/79 |
| PneumocephalusNervous system disorders | 0/84 | 0/83 | 0/83 | 1/73 | 0/83 | 0/79 |
| SyncopeNervous system disorders | 0/84 | 0/83 | 0/83 | 1/73 | 0/83 | 0/79 |
| Psychotic disorderPsychiatric disorders | 0/84 | 0/83 | 0/83 | 1/73 | 0/83 | 0/79 |
| Suicidal ideationPsychiatric disorders | 0/84 | 0/83 | 0/83 | 1/73 | 0/83 | 0/79 |
| Deafness unilateralEar and labyrinth disorders | 0/84 | 0/83 | 0/83 | 0/73 | 0/83 | 1/79 |
| Abscess intestinalInfections and infestations | 0/84 | 0/83 | 0/83 | 0/73 | 0/83 | 1/79 |
| Event | Placebo (Week 0-16) | Apremilast Plus Placebo Injection (Week 0-16) | Etanercept Plus Placebo Tablets (Week 0-16) | Placebo/APR 30mg (Apremilast Exposure Phase) Weeks 16-104 | APR/APR 30 mg (Apremilast Exposure Phase) Weeks 0-104 | Etanercept/APR 30mg (Apremilast Exposure Phase) Weeks 16-104 |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/84 | 9/83 | 1/83 | 13/73 | 12/83 | 6/79 |
| NauseaGastrointestinal disorders | 1/84 | 9/83 | 4/83 | 5/73 | 12/83 | 5/79 |
| HeadacheNervous system disorders | 3/84 | 11/83 | 5/83 | 5/73 | 12/83 | 3/79 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/84 | 6/83 | 2/83 | 5/73 | 9/83 | 1/79 |
| NasopharyngitisInfections and infestations | 8/84 | 4/83 | 8/83 | 4/73 | 5/83 | 5/79 |
| Rebound psoriasisSkin and subcutaneous tissue disorders | 0/84 | 0/83 | 0/83 | 1/73 | 2/83 | 7/79 |
| VomitingGastrointestinal disorders | 2/84 | 4/83 | 2/83 | 3/73 | 6/83 | 2/79 |
| RhinitisInfections and infestations | 1/84 | 4/83 | 4/83 | 1/73 | 6/83 | 2/79 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/84 | 3/83 | 3/83 | 4/73 | 6/83 | 3/79 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 2/84 | 4/83 | 0/83 | 3/73 | 6/83 | 1/79 |
Randomized population includes all randomized participants.
| Age, Continuous(years) | Placebo | Apremilast Plus Placebo Injection | Etanercept Plus Placebo Tablet | Total |
|---|---|---|---|---|
| Mean | 43.4 ± 14.91 | 46.0 ± 13.59 | 47.0 ± 14.07 | 45.4 ± 14.23 |
| Sex: Female, Male(Participants) | Placebo | Apremilast Plus Placebo Injection | Etanercept Plus Placebo Tablet | Total |
|---|---|---|---|---|
| Female | 25 | 34 | 34 | 93 |
| Male | 59 | 49 | 49 | 157 |
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Oct 2012 to primary completion in Jul 2014, 21 months.
Results were first posted in Aug 2015, 1 year 1 month after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 21 months is below that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Apremilast · Etanercept